

Using Cells for Healing

OTCQB: REPCF | TSXV: RP | FRA:P6P2

A Revolution in Sports Medicine and Aesthetics.

We are a regenerative medicine company with innovative cell therapy technology providing unparalleled skin rejuvenation, tendon regeneration, and hair regrowth.

Three applications, two biologics, one game-changing delivery platform

RCS-01:

NBDS Fibroblast Therapy for Aging and Sun-Damaged Skin

RCH-01:

Cell DSC Therapy Androgenetic Alopecia

AESTHETICS

RCI-02: Dermal Injector Device

for

RCT-01 Tendon Repair

Partnered with YOFOTO (China) Health in Greater China

RCS-01 Skin Rejuvenation

Partnered with YOFOTO (China) Health in Greater China

RCH-01 Pattern Baldness

Partnered with Shiseido in Asia

POSITIVE PHASE CLINICAL DATA Randomized

(3:1) double-blind, placebo-controlled trial at UBC Sports Medicine Clinic (Vancovuer) (8 participants)

Primary Endpoint: Safety

Secondary Endpoint: Efficacy at 6 months (function, pain, regeneration, blood flow)

POSITIVE PHASE 1 CLINICAL DATA

Randomized, double-blinded, placebo-controlled trial at IUF Leibniz-Institut für umweltmedizinische Forschung (Dusseldorf)

Primary Endpoint: Safety

Secondary Endpoint: Efficacy at 6 months (biomarkers related so collagen & skin health)

POSITIVE PHASE 1 CLINICAL DATA

Randmized, double-blind, placebo-confrolled trial at Scientific Research Institute for Skin and Venereal Diseases, Department of Dermatology (Tbilisi)

PIVOTAL STUDY IN JAPAN (ongoing)

Data expected 2H 2018; Potential Japanese market launch 2019, Managed and Funded by Shiseido.

Primary Endpoint: Hair Density



NBDS Fibroblast

Chronic Tendinosis

SPORTS MEDICINE

Therapy for

RCI-02 PATENTED DERMAL INJECTION DEVICE

The RCI-02 dermal injector is designed to deliver cells, dermal fillers, drug and biologics.

- Digital controls program for depth, volume, rate of dispersion
- Provides exact repeatable dispersion across 3 dimensions
- Removes human variability
- Built-in Peltier element reduces need for anesthetics
- Near-term commercial launch





Potential to Revolutionize Sports Medicine and Aesthetics

This innovative cell therapy technology has the potential to revolutionize two large consumer-pay markets where few solutions exist.

The Only Regenerative Medicine Company Using Hair Follicle Cell Therapy

We are the only Company using cells derived from hair follicles to potentially heal damaged skin and tendon tissue—offering hope for people with conditions beyond repair.

Multiple Assets Addressing Conditions With Unmet Need

Multi-product portfolio diversifies risk over several programs in two different markets.

Near-Term Commercial Launch And Revenue Catalysts

Patented injection device could generate sales and revenues as early as 2019 in Europe and Hong Kong. Hair regrowth product could be launched in Japanese market as early as 2019.

Hugh Rogers

Director

Multiple Assets Across Large Markets with Key Partnership in Place

Positive phase I clinical data and dermal injector prototypes focused on skin, tendon and hair health (all large markets).

Management Is Commercially-Focused And Strategic

Focus is on leveraging partnership programs and preparing for commercial product launch.

Capital Structure (as at Nov, 2018)

Current market cap. (approx.)	~\$12M
Total money raised through equity to-date	~\$27M
Total revenue to-date (iincluding initial Shiseido licensing payment)	\$3.8M
Current Monthly Burn Rate	~\$180,000
Shares Issued and Outstanding (Basic/FD)	26.8M / 33.4M
Inside Ownership	~21%

Board and Management Team

David Hall Chairman	R. Lee Buckler, B. Ed, LLB President, CEO & Director
Geoff MacKay Director	Dr. Rolf Hoffman, MD Chief Medical Officer
Detect outs OA	Dr. Kavin McElwas BhD Ch

Peter Lewis, CA
Director

Dr. Kevin McElwee, PhD Chief
Scientific Officer

Lee Buckler
Director
Simon Ma CA
Chief Financial Officer

Petra Goessens-Rueck, DVM
Head of Clinical and Regulatory Affairs